Viking claims NASH win after meeting primary endpoint in PhIIb study

Paul Schloesser

Associate Editor

More than three years after kicking off a Phase IIb trial in biopsy-confirmed nonalcoholic steatohepatitis (NASH), Viking Therapeutics says it has a topline win. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Viking claims NASH win after meeting primary endpoint in PhIIb study

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Viking claims NASH win af­ter meet­ing pri­ma­ry end­point in PhI­Ib study

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Viking claims NASH win after meeting primary endpoint in PhIIb study